Arrowhead Pharmaceuticals (ARWR)

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500


Beste broker van 2020 (volgens Beleggers Belangen)
Profiteer van voorbeurs en nabeurs handelen!
Aandelen kopen voor €3.000: €1,80 kosten (o.a. BE&NL)
Vraag het informatiepakket van MeXeM aan


Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

By STEPHEN ADAMS MEDICAL EDITOR FOR THE MAIL ON SUNDAY
PUBLISHED: 01:55 BST, 2 May 2021 | UPDATED: 01:56 BST, 2 May 2021

https://www.dailymail.co.uk/news/articl ... tacks.html

Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks.

The defect raises the amount of a fatty protein called Lipoprotein (a), which is found in potentially dangerous levels in 20 per cent of the population.

It causes blood to clot too easily and cannot be controlled by lifestyle changes.


Researchers are trying to develop new ways of bringing levels down using so-called ‘RNA inhibitors’.
Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks

The aim is to develop a long-lasting injectable drug given only a couple of times a year.

Anglo-German pharmaceutical firm Silence Therapeutics will soon start a small clinical trial of a drug called ‘SLN360’ in the US and Europe.

NHS cardiologist Professor Kausik Ray, director of the Imperial Centre for Cardiovascular Disease Prevention, who is involved in the trial, said: ‘RNA inhibitor therapeutics such as SLN360 have the potential to offer a safe and effective solution for patients, addressing a significant unmet need in cardiovascular disease.’

Swiss firm Novartis recently revealed positive early stage results in patients with very high Lp(a) given weekly injections of its drug with LP(a) levels falling by up to 80 per cent. US-owned company Amgen has seen drops of more than 90 per cent among the first patients treated with its drug called olpasiran.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.





Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Schermafbeelding 2021-05-03 om 13.07.32.png
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Opgelet !! Podcast van 15 aug. 2020


https://podcasts.apple.com/us/podcast/s ... 0487743607
Schermafbeelding 2021-05-03 om 16.56.47.png
Schermafbeelding 2021-05-03 om 16.58.10.png
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Voldoende tweets , nu eens wat resultaten !!
Schermafbeelding 2021-05-03 om 23.35.14.png
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

https://seekingalpha.com/news/3689589-a ... _automated
Schermafbeelding 2021-05-03 om 23.39.19.png
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
maartenverhoeve
Forum veteraan
Forum veteraan
Berichten: 1548
Lid geworden op: 02 jan 2012 21:42
waarderingen: 361

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door maartenverhoeve »

D-day vandaag met overzicht pijplijn en na beurs kwartaalcijfers. Meestal zakt koers na cijfers, Hopelijk deze keer anders.
In port; Enwave, Ageas, Western Cop, Retail estate, RDS, kbca, roularta, Tessenderlo.,oci, Forfarmers, American airlines en veel arrowhead pharma....

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Ales draait blijkbaar rond Arrowhead ;)
Alles lager om nadien te stijgen.
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

http://patft.uspto.gov/netacgi/nph-Pars ... uticals%22

Update to the ANGPLT3 patent was accepted and posted today.
United States Patent 10,995,335
Li , et al. May 4, 2021
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

Abstract
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents. Also disclosed are methods of use of ANGPTL3 RNAi agents and compositions. The ANGPTL3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more ANGPTL3 RNAi agents, optionally with one or more additional therapeutics, are described. Delivery of the ANGPTL3 RNAi agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The RNAi agents can be used in methods of treatment of ANGPTL3-related diseases and disorders, including cardiometabolic diseases such as hypertriglyceridemia and hyperlipidemia.
maartenverhoeve liked last!
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4593
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7822
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

https://ir.arrowheadpharma.com/static-f ... 2788532cfb

PASADENA, Calif.--(BUSINESS WIRE)--May 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021. The company is hosting a conference call today, May 4, 2021, at 4:30 p.m. ET to discuss the results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187.

Selected Recent Events

Announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The interim readout demonstrated that ARO-AAT treatment led to:
Consistent and substantial reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer
Consistent decrease in histological globule burden
Improvements in fibrosis
Improvements in other relevant biomarkers of liver health
Arrowhead intends to present additional interim AROAAT2002 data at an upcoming medical congress, pending abstract acceptance.
Announced ARO-DUX4, Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIMTM) platform. ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD).
Submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic being developed as a treatment for patients with mixed dyslipidemia.
Submitted an IND to the FDA for a Phase 2b dose-finding clinical study of ARO-APOC3, the company’s investigational RNAi therapeutic being developed as a treatment for patients with hypertriglyceridemia.


Schermafbeelding 2021-05-04 om 22.02.46.png
Schermafbeelding 2021-05-04 om 22.02.53.png
https://ir.arrowheadpharma.com/node/16136/pdf
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
VWarena liked last!
Arrowhead (ARWR) is de leidende RNAi-biotech met kandidaat-ontwikkelingsproducten, waaronder acht interne programma's en zes samenwerkende geneesmiddelen, vier met Johnson en Johnson (JNJ), één met Amgen (AMGN) en één met Takeda.

NewB76
Forum veteraan
Forum veteraan
Berichten: 1281
Lid geworden op: 21 jul 2018 13:41
waarderingen: 355

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door NewB76 »

Uit de conference call
Let's move on to our expectations for the near and mid-term. It's going to be a very busy time with several potentially important events and readouts. This is especially true for the next few months, so I'm going to focus on events planned for June and July. We expect to do the following in roughly this order:
1. Dose the first patients in the first ARO-APOC3 Phase 2b study, with a second Phase 2b and a Phase 3 study in patients with FCS planned for shortly thereafter;
2. Dose the first patients in the ARO-ANG3 2001 Phase 2b study;
3. Report initial interim results from the ARO-ENaC first-in-human study. This will likely include the Single Ascending Dose safety results in healthy volunteers, gene knockdown data in the cohort of healthy volunteers that received bronchial brushings and lavage, and data from the first cohort of patients with Cystic Fibrosis;
4. Report full 12-month biopsy results from the 2002 open-label study of AROAAT;
5. Report initial interim results from the ARO-HSD first-in-human study;
6. Present preclinical data on ARO-DUX4 at the FSHD Society International Research Congress;
7. Report initial interim results from the ARO-HIF2 first-in-human study;
8. File a CTA for ARO-DUX4 and potentially host a KOL webinar to discuss the disease, the market opportunity, and the potential development path;
and, 9. Announce additional programs in the pulmonary space that are already deep into preclinical development and in IND-enabling stage.
VWarena liked last!







Plaats reactie